Latest Options News

InVert Graphite has appointed Andrew Lawson as Managing Director following his initial CEO tenure, signaling confidence in his leadership as the company advances its critical minerals projects.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.

Equinox Resources has agreed to sell its Alturas Antimony Project in British Columbia to Maxus Mining, freeing up capital and focus for its core iron ore ambitions in Western Australia.

Summerset Group Holdings Limited has confirmed an ordinary dividend of NZD 0.113 per security for the half-year ending December 2025, alongside key updates to its Dividend Reinvestment Plan pricing and Australian dollar exchange rate.

Generation Development Group Limited has updated its Dividend Reinvestment Plan price to AUD 6.70 per share, accompanying a fully franked ordinary dividend of 1 cent per share for the half-year ending June 2025.

My Foodie Box Limited has raised $500,000 through unsecured promissory notes to support its transformation into Tarrina Resources and relisting on the ASX as a resource exploration company.

Xamble Group Limited has successfully closed a partially underwritten rights issue, raising approximately A$1.36 million to accelerate its digital marketing platform expansion in Southeast Asia.

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.

Resolution Minerals Ltd has successfully raised $25.1 million through a heavily supported placement, positioning itself to advance its Horse Heaven Project in Idaho and prepare for a NASDAQ listing.

Blue Star Helium has decided not to exercise its purchase option on key Colorado helium assets after thorough evaluation, signaling a strategic pivot in its growth approach.

Western Gold Resources has completed over 45% of its 35,300-metre grade control and infill drilling program at the Gold Duke Project, receiving initial assay results from the Eagle prospect. The company is finalizing an updated scoping study and secured $3 million in non-dilutive funding to support a planned mining start in late 2025.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.